Search Result

Results for "

HDAC6+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (3) Apoptosis (34) Autophagy (9) Bcl-2 Family (1) Beta-lactamase (7) c-Myc (1) Caspase (3) Cholinesterase (ChE) (3) Collagen (1) COX (2) DNA-PK (1) DNA/RNA Synthesis (2) Epoxide Hydrolase (1) ERK (1) Free Fatty Acid Receptor (1) HCV (1) HDAC (112) Histone Demethylase (1) Histone Methyltransferase (1) IKK (1) Interleukin Related (3) MDM-2/p53 (1) Microtubule/Tubulin (16) Mitochondrial Metabolism (1) Necroptosis (1) NF-κB (2) NO Synthase (2) Oxidative Phosphorylation (1) p38 MAPK (1) PANoptosis (1) PERK (1) PI3K (1) Pyroptosis (1) RAD51 (1) Reference Standards (4) Tau Protein (2) TNF Receptor (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (80) Cardiovascular Disease (3) Endocrinology (1) Infection (1) Inflammation/Immunology (16) Metabolic Disease (1) Neurological Disease (23)
Click Chemistry:	Alkynes (2)

112

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16026

Ricolinostat Maximum Cited Publications 43 Publications Verification ACY-1215; Rocilinostat	HDAC Apoptosis	Cancer
Ricolinostat (ACY-1215) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 5 nM. ACY-1215 also inhibits *HDAC1, HDAC2, and HDAC3* with IC₅₀s of 58, 48, and 51 nM, respectively.

HY-13271A

Tubastatin A 35+ Cited Publications	Beta-lactamase HDAC Autophagy Apoptosis	Cancer
Tubastatin A is a potent and selective *HDAC6* inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-15994

Citarinostat 3 Publications Verification ACY241	HDAC	Cancer
Citarinostat (ACY241) is a second generation potent, orally active and high-selective *HDAC6* inhibitor with an IC₅₀ of 2.6 nM (IC₅₀s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects .

HY-13271

Tubastatin A Hydrochloride 35+ Cited Publications Tubastatin A HCl; TSA HCl	Beta-lactamase HDAC Autophagy Apoptosis	Cancer
Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective *HDAC6* inhibitor with IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-16699

Nexturastat A 3 Publications Verification	HDAC	Cancer
Nexturastat A is a potent, selective *HDAC6* inhibitor. Nexturastat A has inhibitory for HDAC6 with an IC₅₀ of 5 nM. Nexturastat A can be used for the research of multiple myeloma (MM) .

HY-19327

ACY-738 5 Publications Verification	HDAC	Cancer
ACY-738 is a potent, selective and orally-bioavailable *HDAC6* inhibitor, with an IC₅₀ of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC₅₀s of 94, 128, and 218 nM.

HY-18613

CAY10603 5+ Cited Publications BML-281	HDAC	Cancer
CAY10603 (BML-281) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC₅₀s of 271, 252, 0.42, 6851, 90.7 nM.

HY-138799

KA2507	HDAC	Cancer
KA2507 is a potent, orally active and selective *HDAC6* inhibitor, with an IC₅₀ of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models .

HY-126330

SS-208 AVS100	HDAC	Cancer
SS-208 is a selective *HDAC6* inhibitor, with an IC₅₀ of 12 nM. SS-208 possesses anti-tumor activity in melanoma .

HY-111791

ACY-1083 1 Publications Verification	HDAC	Cancer
ACY-1083 is a selective and brain-penetrating *HDAC6* inhibitor with an IC₅₀ of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy .

HY-153392

TYA-018	Oxidative Phosphorylation HDAC	Cardiovascular Disease
TYA-018 is an orally active, potent and highly selective *HDAC6* inhibitor. TYA-018 can protect heart function in mice. TYA-018 also enhances energetics in mice by increasing expression of targets associated with fatty acid metabolism, protein metabolism, and oxidative phosphorylation .

HY-115475

SW-100 4 Publications Verification	HDAC	Neurological Disease
SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC₅₀ of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier .

HY-161307

T-518	HDAC Microtubule/Tubulin	Neurological Disease
T-518 is an orally active, BBB-penetrant and potent DFMO-based *HDAC6* inhibitor with high selectivity (IC₅₀ = 36 nM). T-518 improves axonal transport. T-518 ameliorates object recognition deficit. T-518 can be studied in research for Alzheimer’s disease and tauopathy .

HY-126147

J22352	HDAC	Cancer
J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective *HDAC6* inhibitor with an IC₅₀ value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1 .

HY-135714

Bavarostat EKZ-001	HDAC Microtubule/Tubulin	Neurological Disease Cancer
Bavarostat (EKZ-001) is a blood-brain barrier-permeable, potent *HDAC6* inhibitor and PET radiotracer, with an IC₅₀ as low as 17 nM against human HDAC6. Bavarostat can be labeled with ¹⁸F and used as a probe to map HDAC6 distribution and measure target occupancy in the brains of non-human primates. Bavarostat also selectively modulates tubulin acetylation, but not histone acetylation. Bavarostat is applicable for research on Alzheimer's disease, other neurodegenerative disorders, and cancers .

HY-130493

HPB HDAC6 inhibitor HPB	HDAC	Cancer
HPB (HDAC6 inhibitor HPB) is a selective *HDAC6* inhibitor with an IC₅₀ of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1 .

HY-100871

WT-161 5+ Cited Publications	Beta-lactamase HDAC Apoptosis	Cancer
WT-161 is a potent and selective *HDAC6* inhibitor with an IC₅₀ of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .

HY-161305

SE-7552	HDAC	Metabolic Disease Cancer
SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate *HDAC6* inhibitor with an IC₅₀ of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice .

HY-135890

CG347B 2 Publications Verification	HDAC	Neurological Disease Inflammation/Immunology Cancer
CG347B is a selective *HDAC6* inhibitor, also involves in synthesis of other metalloenzyme inhibitors. *HDAC6* inhibitors can be used for oncology, immunology, and neurology research .

HY-156274

HDAC6-IN-23	HDAC	Cancer
HDAC6-IN-23 (compound 9) is an orally active *HDAC6* inhibitor .

HY-156850

ITF 3756	HDAC NF-κB	Cancer
ITF 3756 is a selective, orally active *HDAC6* inhibitor. ITF 3756 antagonizes TNF-α-induced activation of the NF-κB pathway. ITF 3756 reduces PD-L1 expression on human monocytes and CD8 ⁺ T cells, and exhibits antitumor activity. ITF 3756 can be used in colon cancer-related research .

HY-161304

HDAC6-IN-33	HDAC	Cancer
HDAC6-IN-33 (compound 6) is a selective and irreversible *HDAC6* inhibitor with an IC₅₀ of 193 nM. HDAC6-IN-33 shows no activity against HDAC1-4. HDAC6-IN-33 is a tight-binding HDAC6 inhibitor capable of inhibiting HDAC6 via a two-step slow-binding mechanism .

HY-120448

QTX125	HDAC Apoptosis	Cancer
QTX125 is a potent and highly selective *HDAC6* inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects .

HY-159109

HDAC6-IN-46	HDAC	Neurological Disease
HDAC6-IN-46 (compound 12) is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC₅₀ value of 6.2 nM. HDAC6-IN-46 can be used in Alzheimer's disease research .

HY-149966

PB131	HDAC	Inflammation/Immunology
PB131 is a selective and brain-permeable *HDAC6* inhibitor with high binding affinity (IC₅₀: 1.8 nM). PB131 has potent anti-inflammatory activity. PB131 can be used for research of inflammation, especially neuroinflammation .

HY-139181

NR160	HDAC	Cancer
NR160 is a selective *HDAC6* inhibitor with an IC₅₀ value of 30 nM. NR160 shows low cytotoxicity against leukemia cell line. NR160 augments the apoptosis induction of Bortezomib (HY-10227) (proteasome inhibitor), Epirubicin (HY-13624) and Daunorubicin (HY-13062A) significantly .

HY-117554

BRD9757	HDAC	Cancer
BRD9757 is a potent, capless and selective *HDAC6* inhibitor with an IC₅₀ of 30 nM. BRD9757 shows excellent selectivity toward HDAC6 versus the class I (>20-fold) and class II (>400-fold) HDACs .

HY-113957

MPI_5a	HDAC	Cancer
MPI_5a is a potent and selective *HDAC6* inhibitor (IC₅₀=36 nM). MPI_5a weakly inhibits other HDAC isoforms. MPI_5a inhibits acyl-tubulin accumulation in cells with an IC₅₀ value of 210 nM .

HY-179019

HDAC-IN-94	HDAC Microtubule/Tubulin Apoptosis Caspase	Neurological Disease Cancer
HDAC-IN-94 is a potent, selective *HDAC6* inhibitor (IC₅₀ = 4.5 nM). HDAC-IN-94 shows >1000-fold selectivity over *HDAC8* and shows minimal activity against other isoforms (HDAC1-3/10). HDAC-IN-94 induces α-tubulin hyperacetylation, apoptosis, and G2/M cell cycle arrest, exhibiting potent anti-tumor efficacy with low cytotoxicity. HDAC-IN-94 can be used for neuroblastoma and glioblastoma research .

HY-150586

PTG-0861	HDAC Apoptosis	Cancer
PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC₅₀ value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers .

HY-151569

SAHA-OH	HDAC Apoptosis	Inflammation/Immunology
SAHA-OH is a selective *HDAC6* inhibitor (IC₅₀=23 nM), shows a 10- to 47-fold selectivity for HDAC6 compared to HDAC 1, 2, 3, and 8. SAHA-OH shows anti-inflammatory activity, and attenuates macrophage apoptosis .

HY-178023

HDAC6-IN-64	HDAC	Cancer
HDAC6-IN-64 (Compound 8) is a *HDAC6* inhibitor with an IC₅₀ of 11.9  nM. HDAC6-IN-64 has poor cell permeability. HDAC6-IN-64 can be used for chemotherapy of cancers like NSCLC research .

HY-178333

HDAC6-IN-66	HDAC	Cancer
HDAC6-IN-66 is a potent and selective histone deacetylase (HDAC) 6 inhibitor with an IC₅₀ of 1.8 nM. HDAC6-IN-66 induces α-tubulin acetylation over histone H3. HDAC6-IN-66 can be used for the research of cancer .

HY-16026R

Ricolinostat (Standard) ACY-1215 (Standard); Rocilinostat (Standard)	HDAC Apoptosis Reference Standards	Cancer
Ricolinostat (Standard) is the analytical standard of Ricolinostat. This product is intended for research and analytical applications. Ricolinostat (ACY-1215) is a potent and selective HDAC6 inhibitor, with an IC50 of 5 nM. ACY-1215 also inhibits HDAC1, HDAC2, and HDAC3 with IC50s of 58, 48, and 51 nM, respectively.

HY-150595

HDAC6-IN-10	HDAC Microtubule/Tubulin	Cancer
HDAC6-IN-10 is a highly selective *HDAC6* inhibitor with the IC₅₀ of 0.73 nM. HDAC6-IN-10 has 144~10941-fold selectivity over other HDAC isoforms. HDAC6-IN-10 shows anti-proliferative activities against multiple myeloma cells .

HY-159171

*sEH/HDAC6-IN-2*	Epoxide Hydrolase HDAC	Neurological Disease Inflammation/Immunology
sEH/HDAC6-IN-2 is a potent dual soluble epoxide hydrolase (sEH) and *HDAC6* inhibitor with IC₅₀s of 0.9 nM, 46.8 nM, and 8 nM for human sEH, mouse sEH, and HDAC6, respectively. sEH/HDAC6-IN-2 can be used for the study of inflammatory pain .

HY-149372

HDAC6-IN-17	HDAC	Cancer
HDAC6-IN-17 (compound 5b) is a potent *HDAC6* inhibitor with IC₅₀ values of 150 nM, 1400 nM, and 2300 nM for HDAC6, HDAC8, and HDAC4, respectively. HDAC6-IN-17 has cytotoxic activity on human cancer cell lines. HDAC6-IN-17 can be used in research of cancer .

HY-13271B

Tubastatin A TFA TSA TFA	HDAC Autophagy Apoptosis	Cancer
Tubastatin A (TSA) TFA is a potent and selective?HDAC6?inhibitor with?IC₅₀?of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A TFA also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein?2 (MBLAC2).

HY-147731

HDAC6-IN-9	HDAC	Cancer
HDAC6-IN-9 (compound 12c) is a potent and selective *HDAC6* inhibitor with IC₅₀ values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities .

HY-176733

HDAC6-IN-61	HDAC Free Fatty Acid Receptor Microtubule/Tubulin ERK	Neurological Disease
HDAC6-IN-61 (Compound 4e) is a *HDAC6* inhibitor (IC₅₀: 73 nM) with selectivity over other HDAC isoforms. HDAC6-IN-61 is also a GPR40 activator. HDAC6-IN-61 increases acetylated tubulin and ERK phosphorylation levels. HDAC6-IN-61 can be used for research of neuroinflammation such as Alzheimer's disease .

HY-141541

MPT0G413	HDAC Tau Protein	Neurological Disease
MPT0G413 (Compound 6) is a potent, selective, orally active and brain-penetrant *HDAC6* inhibitor with an IC₅₀ of 3.92 nM. MPT0G413 decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. MPT0G413 can ameliorate the impaired learning and memory. MPT0G413 can be used for the research of neurological disease, such as Alzheimer's disease .

HY-138831

AES-350	HDAC Apoptosis	Cancer
AES-350 is a potent and orally active *HDAC6* inhibitor with an IC₅₀ and a K_i of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC₅₀ values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research .

HY-151261

HDAC6-IN-13	HDAC	Inflammation/Immunology
HDAC6-IN-13 (Compound 35m) is a potent, highly selective, orally active *HDAC6* inhibitor with an IC₅₀ of 0.019 μM. HDAC6-IN-13 also inhibits *HDAC1, HDAC2* and *HDAC3* with IC₅₀s of 1.53, 2.06 and 1.03 μM, respectively. HDAC6-IN-13 shows significant BBB permeability and anti-inflammatory activity .

HY-146678

HDAC6-IN-5	HDAC Amyloid-β Cholinesterase (ChE)	Neurological Disease
HDAC6-IN-5 (compound 11b) is a potent and BBB-penetrated *HDAC6* inhibitor, with an IC₅₀ of 0.025 μM. HDAC6-IN-5 exhibits strong inhibitory activity against Aβ_1-42 self-aggregation and AChE, with IC₅₀ values of 3.0 and 0.72 μM. HDAC6-IN-5 can enhance neurite outgrowth without significant neurotoxicity .

HY-146679

HDAC6-IN-6	HDAC Amyloid-β Cholinesterase (ChE)	Neurological Disease
HDAC6-IN-6 (compound 6a) is a potent and BBB-penetrated *HDAC6* inhibitor, with an IC₅₀ of 0.025 μM. HDAC6-IN-6 exhibits strong inhibitory activity against Aβ_1-42 self-aggregation and AChE, with IC₅₀ values of 3.0 and 0.72 μM. HDAC6-IN-6 can enhance neurite outgrowth without significant neurotoxicity .

HY-161306

ITF5924	HDAC	Cancer
ITF5924 (compound 1) is a potent and highly selective *HDAC6* inhibitor with an IC₅₀ of 7.7 nM. ITF5924 shows greater than 104-fold selectivity for HDAC6 over all other HDAC subtypes. ITF5924 containing a difluoromethyl-1,3,4-oxadiazole (DFMO) moiety is slow-binding substrate analog of HDAC6 that undergo an enzyme-catalyzed ring opening reaction, forming a tight and long-lived enzyme-inhibitor complex .

HY-178110

HDAC6-IN-65	HDAC Microtubule/Tubulin Histone Methyltransferase	Cancer
HDAC6-IN-65 is a selective *HDAC*6 inhibitor (IC₅₀ = 0.9 nM) and also exhibits a certain suppressive effect on *HDAC3* (IC₅₀ = 39.4 nM). HDAC6-IN-65 can induce the accumulation of α-tubulin (ac-tubulin) and acetylated histone H3 (ac-histone H3, a class I HDAC inhibition marker) in Neuro-2a cells. HDAC6-IN-65 can be used for the study of melanoma .

HY-169940

Fibrostat	HDAC	Inflammation/Immunology
Fibrostat (Compound 5n) is a selective *HDAC6* inhibitor that exerts antifibrotic effects by inhibiting *HDAC6* activity, with an IC₅₀ value of 63 nM. It also exhibits good selectivity over *HDAC1, HDAC3, HDAC5, HDAC8, HDAC10, and HDAC11*. Fibrostat significantly downregulates fibrotic markers (fibronectin and collagen 1) in fibroblasts. Additionally, Fibrostat demonstrated no toxicity in rat-perfused heart and zebrafish larvae models. Fibrostat shows potential for research into fibrosis-related diseases .

HY-162378

LT-630	HDAC	Inflammation/Immunology
LT-630 is a *HDAC6* inhibitor. LT-630 ameliorates liver injury by reducing oxidative damage .

HY-157436

HDAC6-IN-30	HDAC	Cancer
HDAC6-IN-30 (compound 8g) is a selective HDAC6 inhibitor with the IC₅₀ 21 nM, and increase cell protein acetylation levels .

Cat. No.	Product Name	Type

HY-13271AG

Tubastatin A

Fluorescent Dyes

Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective HDAC6 inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

Cat. No.	Product Name	Type

HY-13271AG

Tubastatin A

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N13121

Daphnegiravone D	Flavonoids Flavones Thymelaeaceae Daphne giraldii Nitsche Plants Source Classification	HDAC Apoptosis p38 MAPK
Daphnegiravone D (compound 70) is an HDAC6 inhibitor with anti-hepatocellular carcinoma activity. Daphnegiravone D can induce apoptosis and selectively inhibit the proliferation of liver cancer cells through the p38 and JNK MAPK pathways .

Cat. No.	Product Name		Classification

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active *HDAC6* inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and LSD1 inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-169157

HDAC6-IN-50		Alkynes
HDAC6-IN-50 (Compound 4) is a potent *HDAC6* inhibitor with an IC₅₀ of 35 nM. HDAC6-IN-50 can be used for the study of Parkinson's disease (PD) and Alzheimer's disease (AD) research .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13271AG

Tubastatin A	HDAC Beta-lactamase Autophagy Apoptosis	Cancer
Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective *HDAC6* inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HDAC6+inhibitor

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Click Chemistry

GMP Molecules

Natural
Products